Compare NSP & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | CMPX |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.5M | 927.5M |
| IPO Year | 1996 | 2020 |
| Metric | NSP | CMPX |
|---|---|---|
| Price | $26.50 | $5.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $47.67 | $14.43 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 04-28-2026 | 03-05-2026 |
| Dividend Yield | ★ 8.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,812,000,000.00 | N/A |
| Revenue This Year | $3.45 | N/A |
| Revenue Next Year | $6.95 | $677.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.51 | N/A |
| 52 Week Low | $18.57 | $1.33 |
| 52 Week High | $90.63 | $6.88 |
| Indicator | NSP | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 41.55 |
| Support Level | $18.57 | $4.86 |
| Resistance Level | $48.91 | $5.86 |
| Average True Range (ATR) | 1.72 | 0.29 |
| MACD | 1.15 | 0.01 |
| Stochastic Oscillator | 84.65 | 36.26 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.